INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes. Evidence, technologies, people and the next test—connected, but not confused.
All cards Connections My cards Solid lines: sourced relationships. Dashed: editorial relatedness. Select a card to inspect each link; proximity is not importance.
Topic knowledge graph Commercialization · v4 Shield adoption R&D Allocation · v3 Empire AI resources Frontier Science · v3 Memory resilience Commercialization · v3 Therapy & CDx Frontier Science · v3 AI + scientists Frontier Science · v2 ILC immune signal R&D Allocation · v2 Engram measurement Commercialization · v3 After AI Finds a Cand… R&D Allocation · v1 Who Will Build the Sy… Frontier Science · v1 How Far Can Human Neu… Frontier Science · v1 Can measuring brain f… Frontier Science · v1 What Do New Cells Con… Commercialization · v1 Signatera: Using Tumo… R&D Allocation · v1 Transporting Cell The… Frontier Science · v1 Different Causes, Sim… Commercialization · v1 What Does Chugai Stil… Commercialization · v2 Investing in another … R&D Allocation · v1 What does an AI busin… Frontier Science · v1 Using the same lesson… Commercialization · v1 Changing treatment be… R&D Allocation · v1 Does an antibody that… Frontier Science · v1 Can the same informat… Commercialization · v1 Enspryng expands into… R&D Allocation · v1 Looking across diseas… Frontier Science · v1 Why does the same inf… Commercialization · v1 From testing a patien… R&D Allocation · v1 Building experimental… Frontier Science · v1 ACE levels are lower.… Choose a cardCan Shield Bring More People into Colorectal Cancer Screening? What Research Could Empire AI Make Possible? Why Do Memories Persist When the Brain Keeps Changing? Therapy & companion diagnostics AI–scientist collaboration Immune signals in lobular cancer How to observe an engram After AI Finds a Candidate, What Gets Paid For? Who Will Build the Systems to Oversee Clinical AI? How Far Can Human Neural Tissue Compensate for Lost Function? Can measuring brain function help us choose an antidepressant? What Do New Cells Contribute to a Brain That Preserves Memories? Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery Transporting Cell Therapies Without Refrigeration Different Causes, Similar Psychiatric Symptoms: Protecting the Receptor What Does Chugai Still See in a Drug Roche Is Walking Away From? Investing in another company's drug to advance your own What does an AI business sell when it helps run a clinical trial? Using the same lesson across different actions, without confusing them Changing treatment before scans show progression: a new relationship between breast cancer drugs and blood tests Does an antibody that binds well make a good development candidate? Can the same information remain readable as neural activity changes? Enspryng expands into thyroid eye disease: a different target and a different way to treat Looking across diseases for drugs that treat fibrosis Why does the same inflammation affect some fetuses but not others? From testing a patient's cancer to making their treatment Building experimental data together for cell AI ACE levels are lower. Which functions have changed? SELECTED CARD As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
Loading… Development rights and risk allocation A business comparison of who holds asset rights and bears development costs.
Loading… Explore from here ↗ A small, explicit observation set These selected questions are not a census. A revision can add context without claiming a new event. Editorial links are not funding, causality or scientific validation.